NSE · CONCORDBIO · Pharmaceuticals
Concord Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹261 Cr with net profit ₹61 Cr — a 23.49% net margin, versus 27.62% the period before.
Shareholding
As of 2026-06-30
- Promoter44.08%
- Public39.03%
- FII7.52%
- DII9.36%
83,325 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.73× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #23 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,48,028 Cr | 35.46 | 5.36 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,13,227 Cr | 23.19 | 4.18 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,186 Cr | 31.07 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,258 Cr | 96.25 | 19.94 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹98,075 Cr | 30.44 | 2.57 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,239 Cr | 25.72 | 2.56 | 9.25% | 10.7% |
| Lupin Limited | ₹95,939 Cr | 16.11 | 4.26 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹95,000 Cr | 44.53 | 5.82 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,185 Cr | 21.85 | 6.48 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,949 Cr | 28.06 | 4.62 | 16.66% | 14.31% |
| Concord Biotech Limited(this company) | ₹15,285 Cr | 55.03 | 7.58 | 12.94% | 24.84% |
AI analysis
AI-generated · google/gemini-2.5-flashConcord Biotech Limited has a market capitalization of Rs 13966 Cr. The company's revenue was Rs 1244.53 Cr with revenue growth of 18%. The profit margin is 24.73%.
Positives
- +The debt-to-equity ratio is 0, indicating the company is debt-free.
- +The company reported a profit margin of 24.73%.
- +Promoter holding remains stable at 44.08% as of June 30, 2026.
- +Revenue growth was 18%.
Negatives
- −No quarterly EPS figures have been disclosed since Dec 2024.
- −The number of shareholders decreased from 377572 in August 2023 to 83325 in June 2026.
Financial Performance
In the Mar 2025 annual period, Concord Biotech Limited reported a revenue of Rs 1244.53 Cr and a net profit of Rs 371.64 Cr. Quarterly revenue for Mar 2026 was Rs 326.08 Cr, with a net profit of Rs 88.79 Cr. Revenue grew by 18%.
Profitability & Returns
The company has a Return on Equity (ROE) of 12.94% and a Return on Capital Employed (ROCE) of 17.08%. The profit margin was 24.73%. Earnings per share (EPS) for the Mar 2025 annual period was Rs 35.52.
Balance Sheet
Concord Biotech Limited has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 192.81.
Ownership & Pledges
As of June 30, 2026, promoter holding stands at 44.08%. Public shareholding is 39.03%, while institutional holding is 16.88%. There are no promoter pledges reported.
Data as of — price: 2026-09-18 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.